SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Akira T, Komatsu M, Nango R, Tomooka A, Konaka K, Yamauchi M, Kitamura Y, Nomura S, Tsukamoto I. 1997. Molecular cloning and expression of a rat cDNA encoding 5- aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. Gene 197: 289293.
  • Amin HA, Medeiros LJ, Ma Y, Feretski M, Das P, Leventaki V, Rassidakis GZ, O'Connor SL, McDonnell TJ, Lai R. 2003. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 22: 53995407.
  • Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. 1998. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18: 69516961.
  • Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. 2000. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96: 43194327.
  • Banham AH, Turley H, Pulford K, Gatter K, Macon DY. 1997. The plasma cell associated antigen detectable by antibody VS38 is the p63 regulatory endoplasmic reticulum protein. J Clin Pathol 50: 485489.
  • Barbacid M. 1995. Structural and functional properties of the TRK family of neurotrophin receptors. Ann NY Acad Sci 766: 442458.
  • Barreiro O, Yanez-Mo M, Serrador JM, Montoya MC, Vicente-Manzanares M, Tejedor R, Furthmayr H, Sanchez-Madrid F. 2002. Dynamic interaction of VCAM-1 and ICAM-1 with moeisn and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol 157: 12331245.
  • Basecke J, Griesinger F, Trumper L, Brittinger G. 2002. Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. Ann Hematol 81: 6475.
  • Beardsley GP, Rayl EA, Gunn K, Moroson BA, Seow H, Anderson KS, Vergis J, Fleming K, Worland S, Condon B, Davies J. 1998. Structure and functional relationships in human pur H. Adv Exp Med Biol 431: 221226.
  • Beckmann G, Bork P. 1993. An adhesive domain detected in functionally diverse receptors. Trends Biochem Sci 18: 4041.
  • Beljaards RC, Meijer CJ, Van der Putte SC, Hollema H, Geerts ML, Bezemer PD, Willemze R. 1993. Primary cutaneous T-cell lymphoma: Clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol 172: 5360.
  • Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G. 1998. ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 91: 20762084.
  • Berridge MJ. 1993. Inositol triphosphate and calcium signalling. Nature 361: 315325.
  • Beylot-Barry M, Lamant L, Vergier B, de Muret A, Fraitag S, Delord B, Dubus P, Vaillant L, Delaunay M, MacGrogan G, Beylot C, de Mascarel A, Delsol G, Merlio JP. 1996. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol 149: 483492.
  • Beylot-Barry M, Groppi A, Vergier B, Pulford K, Merlio JP. 1998. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. Blood 91: 46684676.
  • Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ. 1997. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J Biol Chem 272: 16701675.
  • Bischof D, Pulford K, Mason DY, Morris SW. 1997. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17: 23122325.
  • Bitter MA, Franklin WA, Larson RA, McKeithan TW, Rubin CM, Le Beau MM, Stephens JK, Vardiman JW. 1990. Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am J Surg Pathol 14: 305316.
  • Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411: 355365.
  • Bonvini P, Gastaldi T, Falini B, Rosolen A. 2002. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: Down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 62: 15591566.
  • Borer RA, Lehner CF, Eppenberger HM, Nigg EA. 1989. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 56: 379390.
  • Bowden ET, Stoica GE, Wellstein A. 2002. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 277: 3586235868.
  • Bretscher A. 1999. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol 11: 109116.
  • Bretscher A, Edwards K, Fehon RG. 2002. ERM proteins and merlin: Integrators at the cell cortex. Nat Rev Mol Cell Biol 3: 586599.
  • Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, Lui MY, Colleoni GW, Antonescu CR, Ladanyi M, Morris SW. 2001. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 159: 411415.
  • Brodeur GM, Nakagawara A, Yamashira DJ, Ikegaki N, Liu NG, Azar CG, Lee CP, Evans AE. 1997. Expression of TRKA, TRKB and TRKC in human neuroblastomas. J Neurooncol 31: 4955.
  • Brody S, Crystal R. 1993. Adenovirus-mediated in vivo gene therapy. Ann NY Acad Sci 716: 11801184.
  • Bromberg J. 2002. Stat proteins and oncogenesis. J Clin Invest 109: 11391142.
  • Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, Pondarre C, Leverger G, Devalck C, Rodary C, Delsol G, Hartmann O. 1998. CD30(+) anaplastic large-cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92: 35913598.
  • Brugieres L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, Schmitt C, Landmann J, Patte C, Terrier-Lacombe MJ, Delsol G, Hartmann O. 2000. Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children—A report from the French Society of Pediatric Oncology. Ann Oncol 11: 5358.
  • Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857868.
  • Buettner R, Mora LB, Jove R. 2002. Activated STAT signalling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945954.
  • Bullrich F, Morris SW, Hummel M, Pileri S, Stein H, Croce CM. 1994. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. Cancer Res 54: 28732877.
  • Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA. 1995. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 28: 1524.
  • Cataldo KA, Jalal SM, Law ME, Ansell SM, Inwards DJ, Fine M, Arber DA, Pulford KA, Strickler JG. 1999. Detection of t(2;5) in anaplastic large cell lymphoma: Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol 23: 13861392.
  • Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, Daines C, Coffin CM. 2002. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: A study of 135 cases. Mod Pathol 15: 931938.
  • Chakravati V, Kamani NR, Bayerer E, Lange B, Herzog P, Sanders JE, August CS. 1990. Bone marrow transplantation for childhood Ki-1 lymphoma. J Clin Oncol 8: 657660.
  • Chan JK, Cheuk W, Shimizu M. 2001. Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol 25: 761768.
  • Chang F, Steelman LS, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA. 2003. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 22: 469480.
  • Chauhan AK, Li YS, Deuel TF. 1993. Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc Natl Acad Sci USA 90: 679682.
  • Cheuk W, Hill RW, Bacchi C, Dias MA, Chan JK. 2000. Hypocellular anaplastic large cell lymphoma mimicking inflammatory lesions of lymph nodes. Am J Surg Pathol 24: 15371543.
  • Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. 1999. CD30 in normal and neoplastic cells. Clin Immunol 90: 157164.
  • Chiarle R, Gong JZJ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, Piva R, Inghirami G. 2003. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101: 19191927.
  • Chikatsu N, Kojima H, Suzukawa K, Shinagawa A, Nagasawa T, Ozav H, Yamashita Y, Mori N. 2003. ALK+, CD30−, CD20− large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol 16: 828832.
  • Cho H-S, Mason K, Ramifan KX, Stanley AM, Gabelli SB, Denney DWJ, Leahy DJ. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756760.
  • Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. 1997. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57: 18141819.
  • Chung CD, Liao J, Liu B, Rao X, Joy P, Berta P, Shuai K. 1999. Specific inhibition of STAT3 signal transduction by PIAS3. Science 278: 18031805.
  • Claret FX, Hibi M, Dhut S, Toda T, Karin MA. 1996. A new group of conserved co-activators that increase the specificity of AP-1 transcription factors. Nature 383: 453457.
  • Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. 2001. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 14: 569576.
  • Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M. 2000. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 156: 781789.
  • Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. 2002. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4: 529533.
  • Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, Hill DA. 2001. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: A comparative immunohistochemical study. Am J Surg Pathol 25: 13641371.
  • Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A, Marynen P. 2002. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 34: 354362.
  • Cordell JL, Pulford KA, Bigerna B, Roncador G, Banham A, Colombo E, Pelicci PG, Mason DY, Falini B. 1999. Detection of normal and chimeric nucleophosmin in human cells. Blood 93: 632642.
  • Czubayko F, Schulte AM, Berchem GJ, Wellstein A. 1996. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 93: 1475314758.
  • Daly NL, Scanlon MJ, Djordjevic JT, Kroon PA, Smith R. 1995. Three-dimensional structure of a cysteine-rich repeat from the low- density lipoprotein receptor. Proc Natl Acad Sci USA 92: 63346338.
  • Datta SR. 1999. Cellular survival: A play in three Akts. Genes Dev 13: 29052927.
  • De Paepe P, Baens M, van krieken H, Verhasselt B, Stul M, Simons A, Poppe B, Laureys G, Brons P, Vandenberghe P, Speleman F, Praet M, De Wolf-Peeters C, Marynen P, Wlodarska I. 2003. ALK activation by the CTLC-ALK fusion is a recurrent event in B-cell lymphoma. Blood Pub 102: 26382641.
  • DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. 1996. The t(2;5) chromosomal translocation is not a common feature of primary cutaeous CD30+ lymphoproliferative disorders: Comparison with anaplastoc large-cell lymphoma of nodal origin. Blood 87: 34373441.
  • Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW, Mason DY. 1997. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 89: 14831490.
  • Delsol G, Ralfkaier E, Stein H, Wright D, Jaffe ES. 2001. Anaplastic large cell lymphoma. Pathology and genetics. In: JaffeE et al. editors. World Health Organisation of tumours. Tumours of haematopoietic and lymphoid tissues. Lyon: World Health Organisation of tumours. International Agency for Research on Cancer (IACR).
  • Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, Koduru P, Brody JP, Hawson G, Rodwell R, Doody ML, Carnicero F, Reiter A, Goldman JM, Melo JV, Cross NC. 2001. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 98: 37783783.
  • Dirks WG, Fahnrich S, Lis Y, Becker E, MacLeod RA, Drexler HG. 2002. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 100: 4956.
  • Downing JR, Shurtleff SA, Zielenska M, Curcio-Brint AM, Behm FG, Head DR, Sandlund JT, Weisenburger DD, Kossakowska AE, Thorner P, Lorezana A, Ladanyi M, Morris SW. 1995. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood 85: 34163422.
  • Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. 2000. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14: 15331559.
  • Druker BJ. 2002. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1: 3136.
  • Dukers DF, ten Berge RL, Oudejans JJ, Pulford K, Hayes D, Misere JF, Ossenkoppele GJ, Jaspars LH, Willemze R, Meijer CJ. 1999. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. J Clin Pathol 52: 129136.
  • Duyster J, Bai RY, Morris SW. 2001. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20: 56235637.
  • Eggert A, Ikegaki N, Liu XG, Brodeur GM. 2000. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma. Klin Paediatr 212: 200205.
  • Elmberger PG, Lozano MD, Weisenburger DD, Sanger W, Chan WC. 1995. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. Blood 86: 35173521.
  • Englund C, Loren CE, Grabbe C, Deleuil F, Varshney GK, Palmer RH. 2003. Jeb signals via the DAlk receptor tyrosine kinase to drive visceral muscle fusion. Nature (in press).
  • Engstrom M, Karlsson R, Jonsson J-I. 2002. Inactivation of the forkhead transcription factor Fox03 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand. Exp Hematol 31: 316323.
  • Ergin M, Denning MF, Izban KF, Amin HM, Martinez RL, Saeed S, Alkan S. 2001. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp Hematol 29: 10821090.
  • Falini B. 2001. Anaplastic large cell lymphoma: Pathological, molecular and clinical features. Br J Haematol 114: 741760.
  • Falini B, Mason DY. 2002. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: Clinical value of their detection by immunocytochemistry. Blood 99: 409426.
  • Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H. 1995. CD30 (Ki-1) molecule: A new cytokine receptor of the tumour necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 87: 34373441.
  • Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L. 1998. ALK expression defines a distinct group of T/null lymphomas with a wide morphological spectrum. Am J Pathol 153: 875886.
  • Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. 1999a. ALK+ lymphoma: Clinico-pathological findings and outcome. Blood 93: 26972706.
  • Falini B, Pulford K, Pucciarini A, Carbone A, De Wolf-Peeters C, Cordell J, Fizzotti M, Santucci A, Pelicci PG, Pileri S, Campo E, Ott G, Delsol G, Mason DY. 1999b. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 94: 35093515.
  • Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. 1992. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem 267: 2588925897.
  • Fanin RP, Silvestri P, Geromin A, Cerno M, Infanti L, Zaja F, Barillari G, Savignano C, Rinaldi C, Damiani D, Buffoli A, Biffoni F, Baccarini M. 1996. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: Sequential intensive treatment with F-MACHOP regimen (+ radiotherapy) and autologous bone marrow transplantation. Blood 87: 12431248.
  • Fantl JE, Johnson DE, Williams LT. 1993. Signalling by receptor tyrosine kinases. Annu Rev Biochem 62: 453481.
  • Fass D, Blacklow S, Kim PS, Berger JM. 1997. Molecular basis of familial hypercholesterolemia from structure of LDL receptor module. Nature 388: 691693.
  • Feuerstein N, Chan PK, Mond JJ. 1998. Identification of numatrin, the nuclear matrix protein associated with the induction of mitogenesis, as the nucleolar protein B23. Implication for the role of the nucleolus in early transduction of mitogenic signals. J Biol Chem 263: 1060810612.
  • Fiorani C, Vinci G, Sacchi S, Bonaccorsi G, Artusi T. 2001. Primary systemic anaplastic large-cell lymphoma (CD30+): Advances in biology and current therapeutic approaches. Clin Lymphoma 2: 2937; Discussion 38–29.
  • Fouassier L, Yun CC, Fitz JG, Doctor RB. 2000. Evidence for ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) self-association through PDZ-PDZ interactions. J Biol Chem 275: 2503925045.
  • Frank DA. 1999. STAT signalling in the pathogenesis and treatment of cancer. Mol Med 5: 432456.
  • Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T. 1996. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 93: 41814186.
  • Garrido F, Algarra I. 2001. MHC antigens and tumour escape from immune surveillance. Adv Cancer Res 83: 117158.
  • Gascoyne RD. 2001. Therapeutic consequences of pathology and prognostic factors in aggressive NHL− analysis of ALCL. Ann Hematol 80: B45B48.
  • Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD. 1999. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93: 39133921.
  • Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Müller-Hermelink HK, Seymor JF, Horsman DE, Auvigne I, Espinos E, Siebert R, Delsol G. 2003. ALK-positive difuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of six cases. Blood Pub 102: 25682571.
  • Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ, Comoglio PM. 1994. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 13: 35243532.
  • Goldstein JL, Anderson RG, Brown MS. 1979. Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 279: 679685.
  • Golub TR, Barker GF, Lovett M, Gilliland DG. 1994. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukaemia with a t(5;12) chromosomal translocation. Cell 77: 307316.
  • Golub TR, Goga A, Barker G, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG. 1996. Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukaemia. Mol Cell Biol 16: 41074116.
  • Gotoh N, Tojo A, Shibuya M. 1996. A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3. EMBO J 15: 61976204.
  • Gouilleux-Gruart V, Gouilleux F, desaint C, Claisse JF, Capiod JC, Delobel J, Weber-Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B, Prin L. 1996. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukaemia patients. Blood 87: 16921697.
  • Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, Pierotti MA. 1995. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol 15: 61186127.
  • Greco A, Fusetti L, Miranda C, Villa R, Zanotti S, Pagliardini S, Pierotti MA. 1998. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene 16: 809816.
  • Greenland C, Touriol C, Chevillard G, Morris SW, Bai R, Duyster J, Delsol G, Allouche M. 2001. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis. Oncogene 20: 73867397.
  • Greer JP, Flexner JM, Kallianpur AR, Goodman SA, Stein RS, Whitlock JM, Wolf SN, Kinney MC. 1996. Ki-1+ anaplastic large cell lymphoma (ALCL): Correlation of clinical features with p80NPM/ALK expression and histology. Blood 88: 224a.
  • Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A. 1999. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: A role for TNF-R1 activation by endogenous membrane- anchored TNF. EMBO J 18: 30343043.
  • Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. 1999. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 59: 27762780.
  • Gruss H-J, Boiani N, Williams DF, Armitage RJ, Smith EA, Goodwin RG. 1994. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83: 20452091.
  • Haralambieva E, Pulford KA, Lamant L, Pileri S, Roncador G, Gatter KC, Delsol G, Mason DY. 2000. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. Br J Haematol 109: 584591.
  • Helfman DM, Berthier C, Grossman J, Leu M, Ehler E, Perriard E, Perriard JC. 1999. Nonmuscle tropomyosin-4 requires coexpression with other low molecular weight isoforms for binding to thin filaments in cardiomyocytes. J Cell Sci 112: 371380.
  • Herling M, Luthra R, Pugh W, Romaguera J, Morris SW, Falini B, Cabanillas F, Sarris AH. 1998. The t(2;5) and failure-free survival (FFS) of adults with anaplastic large cell lymphoma (ALCL). Blood 92: 224b.
  • Hernandez L, Pinyol M, Hernandez S, Bea S, Pulford K, Rosenwald A, Lamant L, Falini B, Ott G, Mason DY, Delsol G, Campo E. 1999. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94: 32653268.
  • Hernandez L, Bea S, Bellosillo B, Pinyol M, Falini B, Carbone A, Ott G, Rosenwald A, Fernandez A, Pulford K, Mason D, Morris SW, Santos E, Campo E. 2002. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: Identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol 160: 14871494.
  • Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH. 2001. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7: 20312040.
  • Hodges KB, Collins RD, Greer JP, Kadin ME, Kinney MF. 1999. Transformation of the small cell variant Ki1+ lymphoma to anaplastic large cell lymphoma: Pathologic and clinical features. Am J Surg Pathol 23: 4958.
  • Horvath CM, Darnell JE. 1997. The state of the STATs: Recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol 9: 233239.
  • Hoser GI, Majsterek I, Romana DL, Slupianek A, Blasiek J, Skorski T. 2003. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genoxic treatment: Role in drug resistance? Leuk Res 27: 267273.
  • Huff JL, Jelinek MA, Borgman CA, Lansing TJ, Parsons JT. 1993. The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proc Natl Acad Sci USA 90: 61406144.
  • Hutchison RE, Banki K, Shuster JJ, Barrett D, Dieck C, Berard CW, Murphy SB, Link MP, Pick TE, Laver J, Schwenn M, Mathew P, Morris SW. 1997. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol 8: 3742.
  • Hübinger G, Scheffrahn I, Muller E, Bai R, Duyster J, Morris SW, Schrezenmeier H, Bergmann L. 1999. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. Exp Hematol 27: 17961805.
  • Hübinger GE, Muller E, Scheffran I, Schneider C, Hilde E, Singer BA, Sigg I, Graf J, Bergmann L. 2001. CD30-mediated cell cycle arrest associated with induced expression of p21CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 20: 590598.
  • Hübinger G, Wehnes E, Xue L, Morris SW, Maurer U. 2003. Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large cell lymphoma. Exp Hematol 31: 226233.
  • Itoh K, Sakakibara M, Yamasaki S, Takeuchi A, Arase H, Miyazaki M, Nakajima N, Okada M, Saito T. 2002. Cutting edge: Negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton theough Cbp-EBP50-ERM assembly. J Immunol 168: 541544.
  • Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T. 1997. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14: 439449.
  • Jhala DN, Medeiros LJ, Lopez-Terrada D, Jhala NC, Krishnan B, Shahab I. 2000. Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage. A report of two cases arising in HIV-positive patients. Am J Clin Pathol 114: 478482.
  • Johnson PW, Leek J, Swinbank K, Angus B, Roberts P, Markham AF, Selby PJ, MacLennan KA. 1997. The use of fluorescent in situ hybridization for detection of the t(2;5)(p23;q35) translocation in anaplastic large-cell lymphoma. Ann Oncol 8: 6569.
  • Jones D, O'Hara C, Kraus MD, Perez-Atayde AR, Shahsafaei A, Wu L, Dorfman DM. 2000. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 96: 685690.
  • Jäger E, Chen Y-T, Drijfhout J, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old L, Knuth A. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leucocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265270.
  • Jäger E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jäger D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen Y-T, Old LJ, Knuth A. 2000. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97: 47604765.
  • Kadin ME, Morris SW. 1998. The t(2;5) in human lymphomas. Leuk Lymphoma 29: 249256.
  • Kadomatsu K, Huang RP, Suganuma T, Murata F, Muramatsu T. 1990. A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in a spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 110: 607616.
  • Kaneko Y, Frizzera G, Edamura S, Maseki N, Sakurai M, Komada Y, Tanaka H, Sasaki M, Suchi T, et al. 1989. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 73: 806813.
  • Khwaja A. 1999. Akt is more than just a Bad kinase. Nature 401: 3334.
  • Kiehart DP. 1990. Molecular genetic dissection of myosin heavy chain function. Cell 60: 347350.
  • Kikuno R, Nagase T, Suyama M, Waki M, Hirosawa M, Ohara O. 2000. HUGE: A database for human large proteins identified in the Kazusa cDNA sequencing project. Nucleic Acids Res 28: 331332.
  • Kinney MC, Kadin ME. 1999. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am J Clin Pathol 111: S56S67.
  • Kojima S, Inui T, Muramatsu H, Suzuki Y, Kadomatsu K, Yoshizawa M, Hirose S, Kimura T, Sakakibara S, Muramatsu T. 1997. Dimerization of midkine by tissue transglutaminase and its functional implication. J Biol Chem 272: 94109416.
  • Kolibaba KS, Druker BJ. 1997. Protein kinases and cancer. Biochimica et Biophys Acta 1333: F217F248.
  • Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T, Tanaka N. 1997. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15: 12751281.
  • Koon HB, Junghans RP. 2000. Anti-CD30 antibody-based therapy. Curr Opin Oncol 12: 588593.
  • Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW. 1997. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90: 29012910.
  • Kurzrock R, Gutterman J, Talpaz M. 1988. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319: 990998.
  • Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukaemia. Science 278: 13091312.
  • Ladanyi M. 2000. Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms. Am J Pathol 157: 341345.
  • Ladanyi M, Cavalchire G, Morris SW, Downing J, Filippa DA. 1994. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease. Am J Pathol 145: 12961300.
  • Lamant L, Meggetto F, Al Saati T, Brugieres L, de Paillerets BB, Dastugue N, Bernheim A, Rubie H, Terrier-Lacombe MJ, Robert A, Rigal F, Schlaifer D, Shiuta M, Mori S, Delsol G. 1996. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 87: 284291.
  • Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. 1999. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93: 30883095.
  • Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, Mariame B. 2000. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156: 17111721.
  • Lamant L, Gascoyne RD, Duplantier MM, Armstrong F, Raghab A, Chhanabhai M, Rajcan-Separovic E, Raghab J, Delsol G, Espinos E. 2003. Non-muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 37: 427432.
  • Lange K, Uckert W, Blankenstein T, Nadrowitz BC, Renauld J-C, van Snick J, Feller AC, Merz H. 2003. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 22: 517527.
  • Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA. 2000. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 157: 377384.
  • Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, Kadin ME, Vardiman JW. 1989. The t(2;5)(p23;q35): A recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 3: 866870.
  • Le Deley MC, Reiter A. 1999. Prognostic factors in childhood anaplastic large cell lymphoma: Results of the European Intergroup Study. Ann Oncol 10: 28.
  • Lee SY, Kandala G, Liou ML, Liou HC, Choi Y. 1996. CD30/TNF receptor-associated factor interaction: NF-kappaB activation and binding specificity. Proc Natl Acad Sci USA 93: 96999703.
  • Lee H-H, Norris A, Weiss JB, Frasch M. 2003. Drosophila jelly belly signals through the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 425: 507512.
  • Leevers SJ, Vanhaesebroeck B, Waterfield MD. 1999. Signalling through phosphoinositide 3-kinases: The lipids take centre stage. Curr Opin Cell Biol 11: 219225.
  • Leoncini L, Lazzi S, Scano D, Mura A, Onida A, Massarelli G, Tosi P, Barbini P, Cevenini G, Massai MR, Pileri S, Falini B, Giordano A, Kraft R, Laissue JA, Cottier H. 2000. Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity. Int J Cancer 86: 777781.
  • Levi E, Wang Z, Petrogiannis-Haliotis T, Pfeifer WM, Kempf W, Drews R, Kadin ME. 2000. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: A possible mechanism for disease progression. J Invest Dermatol 115: 10341040.
  • Levi E, Pfeifer WM, Kadin ME. 2001. CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: Apoptosis or cell-cycle arrest? Blood 98: 16301632.
  • Loren CE, Scully A, Grabbe C, Edeen PT, Thomas J, McKeown M, Hunter T, Palmer RH. 2001. Identification and characterization of DAlk: A novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells 6: 531544.
  • Loren CE, Englund C, Grabbe C, Hallberg B, Hunter T, Palmer RH. 2003. A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO J 4: 16.
  • Luzi L, Confalonieri S, Di Fiore PP, Pelicci PG. 2000. Evolution of Shc functions from nematode to human. Curr Opin Genet Dev 10: 668674.
  • Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, De Wolf-Peeters C, Wlodarska I, Morris SW. 2000. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 95: 21442149.
  • Ma Z, Hill DA, Collins MH, Morris SW, Sumagi J, Zhon M, Zuppan C, Bridge JA. 2003. Fusion of ALK to the Ran-binding protein 2 (RANBP2) in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37: 98105.
  • Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 1996. 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). J Biol Chem 271: 2144621452.
  • Maes B, Vanhentenrijk V, Wlodarska I, Cools J, Peeters B, Marynen P, de Wolf-Peeters C. 2001. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. Am J Pathol 158: 21852193.
  • Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. 1997. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88: 97107.
  • Mason DY, Bastard C, Rimokh R, Dastague N, Huret JL, Kristoffersson U, Magaud JP, Nezelhof C, Tilly H, Vannier JP, Hemet J, Warnke R. 1990. CD30-positive large cell lymphomas (‘Ki-1 lymphoma’) are associated with a chromosomal translocation involving 5q35. Brit J Haematol 74: 161168.
  • Mason DY, Pulford KA, Bischof D, Kuefer MU, Butler LH, Lamant L, Delsol G, Morris SW. 1998. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 58: 10571062.
  • Mathew P, Morris SW, Kane JR, Shurtleff SA, Pasquini M, Jenkins NA, Gilbert DJ, Copeland NG. 1995. Localization of the murine homolog of the anaplastic lymphoma kinase (Alk) gene on mouse chromosome 17. Cytogenet Cell Genet 70: 143144.
  • Mathew P, Sanger WG, Weisenburger DD, Valentine M, Valentine V, Pickering D, Higgins C, Hess M, Cui X, Srivastava DK, Morris SW. 1997. Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. Blood 89: 16781685.
  • Matsubara S, Take M, Pedraza C, Muramatsu T. 1994. Mapping and characterization of a retinoic acid-responsive enhancer of midkine, a novel heparin-binding growth/differentiation factor with neurotrophic activity. J Biochem (Tokyo) 115: 10881096.
  • Meech SJ, McGavran L, Odom LF, Liang X, Meltesen L, Gump J, Wei Q, Carlsen S, Hunger SP. 2001. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4–anaplastic lymphoma kinase gene fusion. Blood 98: 12091216.
  • Meeker TC, Travis Lay L, Wroblewski JM, Turturro F, Li Z, Seth P. 1997. Adenoviral vectors efficiently target cell lines derived from selected lymphocytoc malignancies, including anaplastic large cell lymphoma and Hodgkin's disease. Clin Cancer Res 3: 357364.
  • Meithing C, Grundler R, Fend F, Hoepfl J, Mugler C, von Schilling C, Morris SW, Peschel C, Duyster J. 2003. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene 22: 46424647.
  • Melo J. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88: 23752384.
  • Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF. 2000. Pleiotrophin signals increased tyrosine phosphorylation of beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci USA 97: 26032608.
  • Mir SS, Richter BW, Duckett CS. 2000. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96: 43074312.
  • Mir SS, Richter BWM, Duckett CS. 2001. Strength of CD30 signal determines sensitivity to apoptosis. Blood 99: 16311632.
  • Mitev L, Christova S, Hadjiev E, Guenova M, Oucheva R, Valkov I, Manolova Y. 1998. A new variant chromosomal translocation t(2;2)(p23;q23) in CD30+/Ki-1+ anaplastic large cell lymphoma. Leuk Lymphoma 28: 613616.
  • Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, Sakai R. 2002. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21: 58235834.
  • Morimoto C, Schlossman SF. 1998. The structure and function of CD26 in the T-cell immune response. Immunol Rev 161: 5570.
  • Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. 1994. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 12811284.
  • Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP. 1997. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14: 21752188.
  • Morris SW, Xue L, Ma Z, Kinney MC. 2001. Alk+ CD30+ lymphomas: A distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol 113: 275295.
  • Motorin Y, Le Caer JP, Waller JP. 1997. Cysteinyl-tRNA synthetase from Saccharomyces cerevisiae. Purification, characterization and assignment to the genomic sequence YNL247w. Biochimie 79: 731740.
  • Muramatsu T. 2002. Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumourigenesis. J Biochem (Tokyo) 132: 359371.
  • Murphy PJ, Kanelakis KC, Galigniana MD, Morishima Y, Pratt WB. 2001. Stoichiometry, abundance, and functional significance of the hsp90/hsp70-based multiprotein chaperone machinery in reticulocyte lysate. J Biol Chem 276: 3009230098.
  • Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. 1998. An induced proximity model for caspase-8 activation. J Biol Chem 273: 29262930.
  • Nadali G, Micheletti M, Chilosi M, Sarris AH, Pizzolo G. 1999. Serum levels of the sCD30 molecules in anaplastic large cell lymphoma (ALCL): Relationship with the expression of ALK p80 protein. Blood 94: 511a.
  • Nagase T, Kikuno R, Ishikawa K, Hirosawa M, Ohara O. 2000. Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 7: 143150.
  • Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, Motoori T, Suzuki R, Kagami Y, Ogura M, Morishima Y, Mizoguchi Y, Okamoto M, Seto M, Koshikawa T, Mori S, Suchi T. 1997. Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 21: 14201432.
  • Nascimento AF, Ruiz R, Hornick JL, Fletcher CD. 2002. Calcifying fibrous “pseudotumor”: Clinicopathologic study of 15 cases and analysis of its relationship to inflammatory myofibroblastic tumor. Int J Surg Pathol 10: 189196.
  • Neckers L, Schulte TW, Mimnaugh E. 1999. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest New Drugs 17: 361373.
  • Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW, Skorski T. 2001. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 61: 65176523.
  • Nishikori M, Maesako Y, Ueda C, Kurata M, Uchiyama T, Ohno H. 2002. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin's disease. Blood 101: 27892796.
  • O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. 1996. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 56: 25152518.
  • O'Dwyer ME, Druker BJ. 2000. STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol 1: 207211.
  • Ohan N, Sabourin D, Booth RA, Liu XJ. 2000. Xenopus laevis TRK-fused gene (TFG) is an SH3 domain binding protein highly expressed in the cement gland. Mol Reprod Dev 56: 336344.
  • Okamoto CT, McKinney J, Jeng YY. 2000. Clathrin in mitotic spindles. Am J Physiol Cell Physiol 279: C369C374.
  • Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K. 2000. Nucleophosmin/B23 is a target of CDK2/cyclin E in centromere duplication. Cell 103: 127140.
  • Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, Morris SW, Kennedy W, Jones SC, Sandlund JT. 2003. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: Report of two cases. Blood 102: 26422644.
  • Orscheschek K, Merz H, Hell J, Binder T, Bartels H, Feller AC. 1995. Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: Indication of a common pathogenesis? Lancet 345: 8790.
  • Ouyang T, Bai R-Y, Bassermann F, von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J. 2003. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J Biol Chem 278: 3002830036.
  • Packham EA, Brook JD. 2003. T-box genes in human disorders. Hum Mol Genet 12: R37R44.
  • Park JP, Curran MJ, Levy NB, Davis TH, Elliott JH, Mohandas TK. 1997. Diffuse large cell, B-cell type lymphoma with a novel translocation (2;22)(p23;q11.2). Cancer Genet Cytogenet 96: 118122.
  • Pasqualucci L, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito G, Falini B, Kadin ME. 1995. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saponin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood 85: 21392146.
  • Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C. 2002. ALK as a novel lymphoma-associated tumor antigen: Identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 99: 21002106.
  • Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, Lazzarino M, Borroni G, Menestrina F, Santucci M. 1993. CD30/Ki-1-positive lymphoproliferative disorders of the skin—Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group. J Clin Oncol 13: 13431354.
  • Pawson T. 1995. Protein molecules and signalling networks. Nature 373: 573580.
  • Pawson T, Gish GD, Nash P. 2001. SH2 domains, interaction modules and cellular wiring. Trends Cell Biol 11: 504511.
  • Perez OD, Kinoshita S, Hitoshi Y, Payan DG, Kitamura T, Nolan GP, Lorens JB. 2002. Activation of the PKB/AKT pathway by ICAM-2. Immunity 16: 5165.
  • Pfeifer W, Levi E, Petrogiannis-Haliotis T, Lehmann L, Wang Z, Kadin ME. 1999. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am J Pathol 155: 13531359.
  • Piccaluga PP, Ascani S, Fraternali Orcioni G, Piccioli M, Pileri A, Jr., Falini B, Pileri S. 2000. Anaplastic lymphoma kinase expression as a marker of malignancy. Application to a case of anaplastic large cell lymphoma with huge granulomatous reaction. Haematologica 85: 978981.
  • Piccinini G, Bacchiocchi R, Serresi M, Vivani C, Rossetti S, Gennaretti C, Carbonari D, Fazioli F. 2002. A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. J Biol Chem 277: 2223122239.
  • Pieples K, Arteaga G, Solaro RJ, Grupp I, Lorenz JN, Boivin GP, Jagatheesan G, Labitzke E, DeTombe PP, Konhilas JP, Irving TC, Wieczorek DF. 2002. Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca(2+) activation. Am J Physiol Heart Circ Physiol 283: H1344H1353.
  • Pillay K, Govender D, Chetty R. 2002. ALK protein expresion in rhabdomyosarcomas. Histopathology 41: 461467.
  • Ponzoni M, Terreni MR, Ferreri AJM, Gerevini S, Anzalone N, Valle M, Pizzolito S, Arrigoni G. 2002. Primary brain CD30+ ALK1+ anaplastic large cell lymphoma (‘ALKoma’): The first case with a combination of ‘not common’ variants. Ann Oncol 13: 18271832.
  • Porsch M, Hofmeyer K, Bausenwein BS, Grimm S, Weber BH, Miassod R, Pflugfelder GO. 1998. Isolation of a Drosophila T-box gene closely related to human TBX1. Gene 212: 237248.
  • Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. 2002. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 277: 1415314158.
  • Pulford K, Mason DY. 2002. CD246 Antigen. Leucocyte Typing VII. In: MasonDY, et al. editors. White cell differentiation antigens. Oxford: Oxford University Press.
  • Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY. 1997. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89: 13941404.
  • Pulford K, Falini B, Cordell J, Rosenwald A, Ott G, Muller-Hermelink HK, MacLennan KA, Lamant L, Carbone A, Campo E, Mason DY. 1999a. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma. Am J Pathol 154: 16571663.
  • Pulford K, Delsol G, Roncador G, Biddolph S, Jones M, Mason DY. 1999b. Immunohistochemical screening for oncogenic tyrosine kinase activation. J Pathol 187: 588593.
  • Pulford K, Falini B, Banham AH, Codrington D, Roberton H, Hatton C, Mason DY. 2000. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 96: 16051607.
  • Pulford K, Roberton H, Banham AH, Hatton CSR. 2002a. Persistence of the immune response to ALK in ALK-positive lymphoma. Proceedings of VIIIth meeting on Malignant Lymphoma.
  • Pulford K, Roberton H, Banham AH, Hatton CS, Mason DY. 2002b. Immunochemical studies of antigenic lymphoma-associated proteins. Br J Haematol 116: 135141.
  • Raetz EA, Perkins SL, Carlson MA, Schooler KP, Carroll WL, Virshup DM. 2002. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. Am J Pathol 161: 875883.
  • Rassidakis GZ, Sarris AH, Herling M, Ford RJ, Cabanillas F, McDonnell TJ, Medeiros LJ. 2001. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol 159: 527535.
  • Rassidakis GZ, Lai R, McDonnell TJ, Cabanillas F, Sarris AH, Medeiros CJ. 2002a. Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol 160: 23092310.
  • Rassidakis GZ, Jones D, Thomaides A, Sen F, Lai R, Cabanillas F, McDonnell TJ, Medeiros LJ. 2002b. Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am J Clin Pathol 118: 328334.
  • Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, McDonnell TJ, Medeiros LJ. 2003a. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely corrleated in systemic anaplastic large cell lymphoma. Clin Cancer Res 9: 11211128.
  • Rassidakis GZ, Oyarzo MP, Medeiros LJ. 2003b. BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Blood 102: 11461147.
  • Rassidakis GZ, Goy A, Medeiros LJ, Jiang Y, Thomaides A, Remache Y, Cabanillas F, Sarris AH, Gilles F. 2003c. Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res 9: 22132220.
  • Rathmell JC, Thompson CB. 1999. The central effectors of cell death in the immune system. Annu Rev Immunol 17: 781828.
  • Raulo E, Julkunen I, Merenmies J, Pihlaskari R, Rauvala H. 1992. Secretion and biological activities of heparin-binding growth-associated molecule. Neurite outgrowth-promoting and mitogenic actions of the recombinant and tissue-derived protein. J Biol Chem 267: 1140811416.
  • Rebecchi MJ, Pentyala SN. 2000. Structure, function and control of phosphoinositide-specific phospholipase C. Physiol Rev 80: 12911335.
  • Reczek D, Bretscher A. 1998. The carboxy-terminal region of EBP50 binds to sites in the aminoterminal domain of ezrin that are masked in the dormant molecule. J Biol Chem 273: 1845218458.
  • Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. 1996. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87: 882886.
  • Reichard KK, McKenna RW, Kroft SH. 2003. ALK-positive B-cell lymphoma: A report of three cases. Mod Pathol 16: 250A.
  • Richter K, Buchner J. 2001. Hsp90: Chaperoning signal transduction. J Cell Physiol 188: 281290.
  • Rimokh R, Magaud JP, Berger F, Samarut J, Coiffier B, Germain D, Mason DY. 1989. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’). Br J Haematol 71: 3136.
  • Roelvink PW, Lizonova A, Lee JG, Bergelson JM, Finberg RW, Brough DE, Koresdi I, Wickham TJ. 1998. The coxsackievirus adenovirus receptor protein can function as a cellular attachment for adenovirus serotypes from subgroups A, C, D, E and F. J Virol 72: 79057915.
  • Rosenwald A, Ott G, Pulford K, Katzenberger T, Kuhl J, Kalla J, Ott MM, Mason DY, Muller-Hermelink HK. 1999. t(1;2)(q21;p23) and t(2;3)(p23;q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood 94: 362364.
  • Ruchatz H, Coluccia AM, Stano P, Marchesi E, Gambacorti-Passerini C. 2003. Constitutive activation of JAK2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp Hematol 31: 309315.
  • Ruiz-Gomez M, Coutts N, Price A, Taylor MV, Bate M. 2000. Drosophila dumbfounded: A myoblast attractant essential for fusion. Cell 102: 189198.
  • Sainati L, Montaldi A, Stella M, Putti MC, Zanesco L, Basso G. 1990. A novel variant translocation t(2;13)(p23;q34) in Ki-1 large cell anaplastic lymphoma. Br J Haematol 75: 621622.
  • Salomoni P, Pandolfi PP. 2002. The role of PML in tumor suppression. Cell 108: 165170.
  • Sandlund JT, Pui CH, Sandlund JT, Pui C-H, Roberts WM, Santan VM, Morris SW, Berard CW, Hutchinson RE, Ribeiro R, Mahmoud H, Crist WM, Rafferty M, Raimondi SC. 1994. Clinicopathlogic features and tretament outcome of chidren with large cell lymphoma and the t(2;5)(p23;q35). Blood 84: 24672471.
  • Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. 1997. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncol 8: 5963.
  • Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. 2001. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19: 23192333.
  • Scheijen B, Griffin JD. 2002. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 21: 33143333.
  • Schlessinger J. 2000. Cell signalling by receptor tyrosine kinases. Cell 103: 211225.
  • Schneider C, Hübinger G. 2002. Pleiotropic signal transduction mediated by human CD30: A member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 43: 13551366.
  • Schulte AM, Wellstein A. 1997. Pleiotrophin and related molecules. Tumour angiogenesis. Oxford, New York, Tokyo: Oxford University press.
  • Schulte AM, Lai S, Kurtz A, Czubayko F, Riegel AT, Wellstein A. 1996. Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus. Proc Natl Acad Sci USA 93: 1475914764.
  • Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schadt M, Diehl V. 1982. Production of a monoclonal antibody specific for Hodgkin's disease and a subset of normal lymphoid cells. Nature 299: 6567.
  • Sgambato A, Cittadini A, Faraglia B, Weinstein IB. 2000. Multiple functions of p27Kip1 and its alterations in tumour cells: A review. J Cell Physiol 183: 1827.
  • Shao CK, Su ZL, Feng ZY, Rao HL, Tang LY. 2002. Significance of ALK gene expression in neoplasms and normal tissues. Ai Zheng 21: 5862.
  • Shiota M, Mori S. 1996. The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Leuk Lymphoma 23: 2532.
  • Shiota M, Mori S. 1997. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Leukemia 11(Suppl 3): 538540.
  • Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. 1994a. Hyperphosphorylation of a novel 80 kDa protein tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9: 15671574.
  • Shiota M, Fujimoto J, Taneka M, Satoh H, Ichinohasama R, Abe M, Nakano M, Yamamoto T, Mori S. 1994b. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 84: 36483652.
  • Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A, Nanba K, Takami K, Takami S, Yamabe H, Takano Y, Izumo T, Nagatami T, Mohri N, Nasu K, Satoh H, Katano M, Fujimoto J, Yamamoto T, Mori S. 1995. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 86: 19541960.
  • Siebert R, Gesk S, Harder L, Steinemann D, Grote W, Schlegelberger B, Tiemann M, Wlodarska I, Schemmel V. 1999. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. Blood 94: 36143617.
  • Sigel JE, Smith TA, Reith JD, Goldblum JR. 2001. Immunohistochemical analysis of anaplastic lymphoma kinase expression in deep soft tissue calcifying fibrous pseudotumor: Evidence of a late sclerosing stage of inflammatory myofibroblastic tumor? Ann Diagn Pathol 5: 1014.
  • Simonitsch I, Panzer-Gruemayer ER, Ghali DW, Zoubek A, Radaszkiewicz T, Gadner H, Kovar H. 1996. NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki-1 positive anaplastic large cell lymphomas. Br J Haematol 92: 866871.
  • Simonitsch I, Polgar D, Hajek M, Duchek P, Skrzypek B, Fassl S, Lamprecht A, Schmidt G, Krupitza G, Cerni C. 2001. The cytoplasmic truncated receptor tyrosine kinase ALK homodimer immortalizes and cooperates with ras in cellular transformation. FASEB J 15: 14161418.
  • Sirvent N, Hawkins AL, Moeglin D, Coindre JM, Kurzenne JY, Michiels JF, Barcelo G, Turc-Carel C, Griffin CA, Pedeutour F. 2001. ALK probe rearrangement in a t(2;11;2)(p23;p15;q31) translocation found in a prenatal myofibroblastic fibrous lesion: Toward a molecular definition of an inflammatory myofibroblastic tumor family? Genes Chromosomes Cancer 31: 8590.
  • Skinnider BF, Connors JM, Sutcliffe SB, Gascoyne RD. 1999. Anaplastic large cell lymphoma: A clinicopathologic analysis. Hematol Oncol 17: 137148.
  • Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T. 2001. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61: 21942199.
  • Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. 2002. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22: 41894201.
  • Sonoda E, Sasaki MS, J.M B, Bezzubova O, Shinohara A, Ogawa H, Takata M, Yamaguchiiwai Y, Takeda S. 1998. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 17: 598608.
  • Souttou B, Carvalho NB, Raulais D, Vigny M. 2001. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 276: 95269531.
  • Spudich JA. 1994. How molecular motors work. Nature 372: 515518.
  • Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. 1997. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 89: 239250.
  • Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. 2000. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 96: 36813695.
  • Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A. 2001. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 276: 1677216779.
  • Stoica GE, Kuo A, Powers C, Bowden ET, Buchert-Sale E, Riegel AT, Wellstein A. 2002. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277: 3599035999.
  • Su LD, Schnitzer B, Ross CW, Vasef M, Mori S, Shiota M, Mason DY, Pulford K, Headington JT, Singleton TP. 1997. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. J Cutan Pathol 24: 597603.
  • Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, Mori N, Kojima M, Yoshino T, Yamabe H, Shiota M, Mori S, Ogura M, Hamajima N, Seto M, Suchi T, Morishima Y, Nakamura S. 2000. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96: 29933000.
  • ten Berge RL, Dukers DF, Oudejans JJ, Pulford K, Ossenkoppele GJ, de Jong D, Misere JF, Meijer CJ. 1999. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 93: 26882696.
  • ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Pulford K, Willemze R, Falini B, Chott A, Meijer CJ. 2000. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 53: 445450.
  • ten Berge RL, Oudejans JJ, Dukers DF, Meijer JW, Ossenkoppele GJ, Meijer CJ. 2001. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: An independent biological prognostic marker. Leukemia 15: 458464.
  • ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ, Oudejans JJ. 2002. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99: 45404546.
  • ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. 2003. ALK-negative systemic anaplastic large cell lymphoma: Differential diagnostic and prognostic aspects—A review. J Pathol 200: 415.
  • Tian ZG, Longo DL, Funakoshi S, Asai O, Ferris DK, Widmer M, Murphy WJ. 1995. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 55: 53355341.
  • Tomoda K, Kubota Y, Kato J. 1999. Degradation of the cyclin dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398: 160165.
  • Tort F, Pinyol M, Pulford K, Roncador G, Hernandez L, Nayach I, Kluin-Nelemans HC, Kluin P, Touriol C, Delsol G, Mason D, Campo E. 2001. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 81: 419426.
  • Touriol C, Greenland C, Lamant L, Pulford K, Bernard F, Rousset T, Mason DY, Delsol G. 2000. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 Cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95: 32043207.
  • Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, Pelicci PG, Falini B. 2000. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 60: 793798.
  • Trumper L, Pfreundschuh M, Bonin FV, Daus H. 1998. Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals. Br J Haematol 103: 11381144.
  • Tsukita S, Yonemura S. 1999. Cortical actin organization: Lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem 274: 3450734510.
  • Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S. 1994. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126: 391401.
  • Tsukita S, Yonemura S, Tsukita S. 1997. ERM proteins: Head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci 22: 5358.
  • Turturro F, Seth P, Link CJ, Jr. 2000a. In vitro adenoviral vector p53-mediated transduction and killing correlates with expression of coxsackie-adenovirus receptor and alpha(nu)beta5 integrin in SUDHL-1 cells derived from anaplastic large- cell lymphoma. Clin Cancer Res 6: 185192.
  • Turturro F, Heineke HL, Drevyanko TF, Link CJ Jr, Seth P. 2000b. Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model. Gene Ther 7: 930933.
  • Turturro F, Frist AY, Arnold MD, Pal A, Cook GA, Seth P. 2001a. Comparison of the effects of recombinant adenovirus-mediated expression of wild-type p53 and p27Kip1 on cell cycle and apoptosis in SUDHL-1 cells derived from anaplastic large cell lymphoma. Leukemia 15: 12551231.
  • Turturro F, Frist AY, Arnold MD, Seth P, Pulford K. 2001b. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27(Kip1). Oncogene 20: 44664475.
  • Turturro F, Frist AY, Arnold MD. 2001c. Effects of the inhibition of NPM-ALK kinase activity by 17-allylamino-17-demethoxygeldanamycin (17-AAG). Blood 98(11): 456a, Abstract 1944.
  • Turturro F, Arnold MD, Frist AY, Seth P. 2002a. Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease. Leuk Lymphoma 43: 13231328.
  • Turturro F, Arnold MD, Frist AY, Pulford K. 2002b. Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin Cancer Res 8: 240245.
  • Turturro F. 2003a. Recombinant adenovirus-mediated cytotoxic gene therapy and lymphoproliferative disorders: Analysis based on pharmacodynamics. Curr Drug Targets Immune Endocr Metabol Disord 2: 109118.
  • Turturro F. 2003b. Recombinant adenovirus-mediated cytotoxic gene therapy of lymphoproliferative disorders: Is CAR important for the vector to ride? Gene Ther 10: 100104.
  • van der Geer P, Wiley S, Gish GD, Pawson T. 1996. The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. Curr Biol 6: 14351444.
  • Villalva C, Trempat PFB, Delsol G, Brousset P. 2001. BCL-2 expression in anaplastic large cell lymphoma. Am J Pathol 158: 18891890.
  • Villalva C, Trempat P, Greenland C, Thomas C, Girard JP, Moebius F, Delsol G, Brousset P. 2002. Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma. Br J Haematol 118: 791798.
  • Waggott W, Lo YM, Bastard C, Gatter KC, Leroux D, Mason DY, Boultwood J, Wainscoat JS. 1995. Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma. Br J Haematol 89: 905907.
  • Waggott W, Delsol G, Jarret RF, Mason DY, Gatter KC, Boultwood J, Wainscoat JS. 1997. NPM-ALK gene fusion and Hodgkin's disease. Blood 90: 17121713.
  • Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, Chace DF, Siegall CB, Francisco JA. 2002. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 62: 37363742.
  • Warrick HM, Spudich JA. 1987. Myosin structure and function in cell motility. Annu Rev Cell Biol 3: 379421.
  • Weber-Matthiesen K, Deerberg-Wittram J, Rosenwald A, Poetsch M, Grote W, Schlegelberger B. 1996. Translocation t(2;5) is not a primary event in Hodgkin's disease. Simultaneous immunophenotyping and interphase genetics. Am J Path 149: 463468.
  • Weiss LM, Lopategui JR, Sun LH, Kamel OW, Koo CH, Glackin C. 1995. Absence of the t(2;5) in Hodgkin's disease. Blood 85: 28452847.
  • Weiss JB, Suyama KL, Lee HH, Scott MP. 2001. Jelly belly: A Drosophila LDL receptor repeat-containing signal required for mesoderm migration and differentiation. Cell 107: 387398.
  • Wellmann A, Otsuki T, Vogelbruch M, Clark HM, Jaffe ES, Raffeld M. 1995. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Blood 86: 23212328.
  • Wellmann A, Doseeva V, Butscher W, Raffeld M, Fukushima P, Stetler-Stevenson M, Gardner K. 1997. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. Faseb J 11: 965972.
  • Wellstein A, Fang WJ, Khatri A, Lu Y, Swain SS, Dickson RB, Sasse J, Riegel AT, Lippman ME. 1992. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem 267: 25822587.
  • Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. 1998. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18: 15171524.
  • Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR. 2002. Anaplastic large cell lymphoma in childhood: Analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 117: 812820.
  • Wilson J. 1996. Adenoviruses as gene-delivery vehicles. N Engl J Med 334: 11851187.
  • Woetmann A, Nielsen M, Christensen ST, Brockdorff J, Kaltoft K, Engel AM, Skor S, Brender C, Geisler G, Svejgaard A, Rygaard J, Leick V, Odum N. 1999. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci USA 96: 1062010625.
  • Wood GS. 1998. Analysis of the t(2;5)(p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Leuk Lymphoma 29: 93101.
  • Wood GS, Hardman DL, Boni R, Dummer R, Kim YH, Smoller BR, Takeshita M, Kikuchi M, Burg G. 1996. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood 88: 17651770.
  • Xerri L, Parc P, Hassoun J, Birnbaum D. 1996. Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease. J Pathol 178: 128132.
  • Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, Fletcher JA. 1998. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 18: 8487.
  • Ybe JA, Brodsky FM, Hofmann K, Lin K, Liu SH, Chen L, Earnest TN, Fletterick RJ, Hwang PK. 1999. Clathrin self-assembly is mediated by a tandemly repeated superhelix. Nature 399: 371375.
  • Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, Carroll AJ, Morris SW. 1996. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 12: 265275.
  • Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S, Tsukita S. 1998. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43 and ICAM-2. J Cell Biol 140: 885895.
  • Yousem SA, Shaw H, Cieply K. 2001. Involvement of 2p23 in pulmonary inflammatory pseudotumors. Hum Pathol 32: 428433.
  • Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G. 2002. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21: 10381047.
  • Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA. 2002. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168: 466474.